Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 729

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 729
---
 |
| Common shares, CHF 0.80 ($0.80) par value, 3,159,535 and 810,722 registered shares issued and outstanding at December 31, 2024 and 2023, respectively |     |              |     166,353 |   |     |      |     668,555 |   |
| Additional paid-in capital                                                                                                                            |     |              |  72,820,671 |   |     |      |  61,029,437 |   |
| Accumulated deficit                                                                                                                                   |     |              | (74,430,474 | ) |     |      | (70,373,484 | ) |
| Accumulated other comprehensive loss                                                                                                                  |     |              |     108,853 |   |     |      |    (158,071 | ) |
| Total shareholders’ equity (deficit)                                                                                                                  |     |              |   1,406,361 |   |     |      |  (8,833,563 | ) |
| Total liabilities and shareholders’ equity (deficit)                                                                                                  |     | $            |   2,233,125 |   |     | $    |   1,846,641 |   |

The accompanying notes are an integral part of these consolidated financial statements.

Annex F-4

NLS PHARMACEUTICS LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

| OPERATIONS:                                                                                     
 Operating expenses:                                                                             |     | For the Years Ended December 31, 
 2024                             |            |   |     | 2023 |             |   |     | 2022 |             |   |
|:------------------------------------------------------------------------------------------------|:----|:---------------------------------|-----------:|:--|:----|:-----|------------:|:--|:----|:-----|------------:|:--|
| Research and development                                                                        |     | $                                |    422,051 |   |     | $    |   5,908,288 |   |     | $    |   8,976,643 |   |
| General and administrative                                                                      |     |                                  |  3,214,224 |   |     |      |   5,898,775 |   |     |      |   6,505,721 |   |
| Merger transaction costs                                                                        |     |                                  |